Given the oncogenic role of MALAT1 in the progression and drug resistance in GC, the suppression of MALAT1 by ASOs hold immense therapeutic potential for GC treatment, which await further investigation both in the preclinical and clinical settings in the context of GC (105–107). The gene discussed is MALAT1; the disease is gastric cancer.